Abstract
Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
Keywords: Proteasome inhibitor, bortezomib, adverse effect, resistance.
Current Pharmaceutical Design
Title:Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Volume: 19 Issue: 18
Author(s): Biyin Cao, Jie Li and Xinliang Mao
Affiliation:
- Cyrus Tang Hematology Center, Soochow University, 199 Ren Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu Province, 215123, P.R.China.,China
Keywords: Proteasome inhibitor, bortezomib, adverse effect, resistance.
Abstract: Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
Export Options
About this article
Cite this article as:
Cao Biyin, Li Jie and Mao Xinliang, Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction, Current Pharmaceutical Design 2013; 19(18) . https://dx.doi.org/ 10.2174/13816128113199990338
DOI https://dx.doi.org/ 10.2174/13816128113199990338 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Targeting Signaling Pathways in Multiple Myeloma
Current Pharmaceutical Biotechnology Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Recent Advances in Chemotherapeutic Implications of Deguelin: A Plant- Derived Retinoid
The Natural Products Journal Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Effects of Highly Active Antiretroviral Therapy on HIV-1-Associated Oral Complications
Current HIV Research Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Application of RNA Interference for the Control of Female Reproductive Functions
Current Pharmaceutical Design Epigenetic Regulation and Therapeutic Approaches in Cancer
Current Topics in Medicinal Chemistry Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis
Current Medicinal Chemistry Preface (Hot Topic: Bioactive Peptides from Food Proteins Executive Editor: Antonio Pellegrini )
Current Pharmaceutical Design Phage Display Derived Therapeutic Antibodies
Current Pharmaceutical Biotechnology Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets A Filter Based Feature Selection Algorithm Using Null Space of Covariance Matrix for DNA Microarray Gene Expression Data
Current Bioinformatics Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry The physics for the formation of cell-in-cell structures.
Current Molecular Medicine